In enteric ReA, active bowel inflammation affects the barrier function of the gut wall, allowing gut flora to access systemic sites [ 45].
In enteric ReA active bowel inflammation will inevitably affect the barrier function of the gut wall, allowing systemic access by gut flora.
This translocation is supported by increased levels of lipopolysaccharide which is a surrogate parameter of gram-negative bacteremia [8], bacterial overgrowth in the small bowel [9], and decreased barrier function of the intestine in patients with liver cirrhosis [10].
Healthy individuals carry a large intestinal load of LPS with no harm, and it is generally accepted that in order for the pathogenesis to occur, the barrier function of the gut must firstly be compromised, as in inflammatory bowel disease in man [ 2, 24], stress in pigs [ 25], nematode infection in mice [ 26] and sub-acute ruminal acidosis (SARA) in cattle [ 22].
As a consequence of tissue ischemia, the 'mechanical barrier' as well as 'immunologic' and 'ecological' barrier functions of the bowel wall might break down and lead to 'bacterial overgrowth' with BT [11, 48, 49].
As a consequence of tissue ischemia, the 'mechanical barrier' as well as 'immunologic' and 'ecological' barrier functions of the bowel wall might break down and lead to 'bacterial overgrowth' with BT [ 11, 48, 49].
111 Butyrate improves the barrier function of intestinal epithelia and has the potential to treat inflammatory bowel disease.
Similar mechanisms might also be operating in inflammatory bowel diseases (IBDs) where HIF-1 regulates the barrier function of the intestinal mucosa [37].
Ulceration could disrupt the mucosal barrier and thereby abrogated the protective barrier function of the epithelium.
Ultimately, the barrier function of epithelium is lost thereby.
